Introduction
In prescribing drug therapy and subsequent patient treatment, there are numerous risks that the professional clinician must consider. One such factor should be the withdrawal of medication at the end of the course. Strictly speaking, medication withdrawal refers to the point in the course of overall treatment when a patient stops taking a medication, a critical step that requires careful monitoring to avoid adverse effects (Horowitz et al., 2023). These effects include the well-known withdrawal syndrome, during which the body experiences a state of psychophysiological need to continue taking the drug, and the resulting outcomes of reduced quality of life. This paper offers a critical discussion of strategies and aspects of drug therapy withdrawal with the support of scientific evidence through four case studies.
Patient on Opioid Analgesics
The first scenario was a 36-year-old man who had been on a three-year course of opioid analgesics for treatment and was also taking clonazepam (1 mg, BID) from a group of benzodiazepine derivatives. Such a decision on combination therapy should have a strong medical rationale, as it is well known that the coadministration of benzodiazepines and opioids can hurt the respiratory system, posing a threat to respiratory depression (NIH, 2022). Additionally, it cannot be excluded that clonazepam enhances the effects of opioids on the nervous system, which in turn increases the risk of overdose. If the prescription of combination therapy is still necessary, it is important to consider the correct strategy for clonazepam withdrawal after completion of the course.
First, the patient should be monitored by the treating physician on an ongoing basis to reduce the threats of withdrawal and the return of panic attacks (Horowitz et al., 2023). Regular consultations with the physician should be the basis of medication withdrawal to discuss potential worries and fears. Second, it is recommended that clonazepam not be discontinued abruptly but rather reduced gradually over at least several weeks (Baldwin, 2022).
Alternatively, selective serotonin reuptake inhibitors, including Sertraline, may be prescribed as an alternative medication to reduce the risks of combination therapy, starting with a low dose and gradually increasing the dose as needed (Perananthan & Buckley, 2021). Side effects, including psychosomatic effects, are possible in the first weeks of therapy; therefore, the initiation of prescription should be implemented strictly with regular medical supervision. To prescribe antidepressants, it is important to exercise caution and continuously check the efficacy of treatment to adjust therapy promptly if necessary.
There are legal, ethical, and social nuances in the proposed strategy that should be considered when prescribing treatment. Ethically, it is important to ensure that the patient appears fully informed and gives voluntary consent to the therapy (Glaser et al., 2020). The patient should be made aware of potential side effects due to clonazepam withdrawal and Sertraline prescription. In terms of legal accountability, it is important that the physician’s prescriptions comply with medical standards and that all patient complaints and needs are heard (Scognamiglio et al., 2023).
The physician should maintain accountable documentation of all changes in the patient’s therapy and make the patient aware of the risks involved. Finally, from a social perspective, it is important to ensure that the patient is socially safe: the man should be supported at every stage of therapy. If existing support from family members and the physician is insufficient, the patient may be encouraged to attend counseling with a psychologist or group therapy sessions to awaken internal resources.
Patient with Panic Attacks
The second scenario discusses the case of a 42-year-old woman who is experiencing panic attacks. The patient is currently taking alprazolam (1 mg, BID) â the woman sees efficacy in the therapy and wants to discontinue the medication, but experiences signs of withdrawal each time. The most commonly experienced symptoms when alprazolam use is reduced are headaches and vertigo, increased anxiety, sleep quality disturbances, and muscle spasms (Cosci & Chouinard, 2020). The manifestations of the above signs can be minimized medically. Still, it is correct to note that a woman can also experience more serious withdrawal symptoms, namely, body convulsions and hallucinations.
If a patient experiences these, urgent medical attention is required (Horowitz et al., 2023). Switching to diazepam from the group of long-acting benzodiazepines may be a viable solution, as this drug is known to be more stable than alprazolam, meaning that the onset of withdrawal symptoms may be less severe (Jufer-Phipps & Levine, 2020; Cunha, 2022). To begin, the patient should be switched to a 10 mg BID dose and then gradually reduced by 0.5 mg every 2 weeks (OHA, 2021). This would allow for a more seamless withdrawal of the patient from the medication and allow for easier withdrawal.
Pregnant Patient with Anxiety
The present scenario is a case study of a young pregnant woman who is taking lorazepam (1 mg, TID) for the treatment of increased anxiety. This medication is an effective treatment for anxiety disorder, and the woman’s personal experience supports this (Jones & Husain, 2021). However, there are some risks to both the woman and the fetus that should be considered when continuing therapy. The development of psychophysical dependence on the drug and the possibility of side effects (respiratory disturbances, high drowsiness) are such consequences (Meng et al., 2023).
In addition, it is well known that taking the drug during pregnancy can lead to the development of fetal abnormalities (NHS, 2023). The development of withdrawal symptoms in the neonate is also possible if the woman does not stop taking the drug (Horowitz et al., 2023). As with other benzodiazepines, the reduction of their intake should be carried out through a slight decrease in the dosage taken. Continuous medical supervision and necessary correction are necessary to exclude the development of undesirable effects and the return of anxiety.
Abrupt termination of intake may lead to the manifestation of withdrawal symptoms and anxiety, which will sharply worsen the quality of life and the course of pregnancy of the patient. It is important to continue therapy because untreated anxiety symptoms can increase the risks of fetal defects and weight loss, as well as affect the development of postpartum depression (Shariatpanahi et al., 2023). Since lorazepam is recommended to be discontinued, women can be switched to psychological therapy or Sertraline, which shows no risks to the fetus and mother for the duration of pregnancy and breastfeeding (OTIS, 2021). In other words, it is recommended to switch to alternative treatments for anxiety disorder without jeopardizing the child or the woman.
Patient with Comorbid Disorders
The last scenario is the story of an elderly patient who is continuously taking a complex of medications for various pathologies and disorders, including clonazepam (1 mg, TID). The man is experiencing constant memory and concentration loss, leading him to stumble and fall even in familiar surroundings. It is known that continued use of clonazepam as a benzodiazepine medication can lead to increased dizziness and drowsiness as side effects, which in turn can be a cause of falls (Goldin, 2023).
In addition, the risks and side effects of benzodiazepines should include cognitive impairment and impaired coordination, as well as the threat of developing psychophysiological dependence on the drug. It is recommended that the clinician carefully examine the patient for sleep quality and memory lapses, using a standardized instrument such as the MMSE (Arevalo-Rodriguez et al., 2021). If the man has been injured during falls, this should also be identified during the examination.
As before, it is recommended to gradually reduce the dosage of the drug under the continuous supervision of the treating physician to reduce the risk of developing withdrawal signs, which can only make life worse for the elderly patient (Horowitz et al., 2023; Baldwin, 2022). If abruptly discontinued, a man may experience problems with increased anxiety and insomnia, as well as some muscle spasms, which, in the context of an elderly patient, may lead to additional falls and injuries. The patient is advised to seek psychological support for regular monitoring of the conditions. If any of the named signs of withdrawal appear, the treating physician should be contacted for help.
Conclusion
In the present paper, four patient scenarios with different characteristics and medical histories, each with a risk of experiencing withdrawal syndrome, were examined in detail. The patients were taking medications whose abrupt discontinuation could lead to side effects or even a return of the symptoms that caused the medication to be started. For this reason, everyone was advised to slowly reduce the dosage of the medication they were taking under the continuous supervision of a physician to eliminate the risk of adverse effects on their health and well-being. In addition, patients were advised to either switch to other drugs that did not pose such significant risks or to seek psychological support to obtain professional help.
References
Arevalo-Rodriguez, I., Smailagic, N., RoquĂŠ-Figuls, M., Ciapponi, A., Sanchez-Perez, E., Giannakou, A., & Cullum, S. (2021). MiniâMental State Examination (MMSE) for the early detection of dementia in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews, (7), 1-70.
Baldwin, D. S. (2022). Clinical management of withdrawal from benzodiazepine anxiolytic and hypnotic medications. Addiction, 117(5), 1472-1482.
Cosci, F., & Chouinard, G. (2020). Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychotherapy and Psychosomatics, 89(5), 283-306.
Cunha, J. P. (2022). Alprazolam vs. Diazepam. MedicineNet.
Glaser, J., Nouri, S., Fernandez, A., Sudore, R. L., Schillinger, D., Klein-Fedyshin, M., & Schenker, Y. (2020). Interventions to improve patient comprehension in informed consent for medical and surgical procedures: An updated systematic review. Medical Decision Making, 40(2), 119-143.
Goldin, D. S. (2023). Fast facts for psychopharmacology for nurse practitioners. Springer Publishing.
Horowitz, M. A., Framer, A., Hengartner, M. P., Sørensen, A., & Taylor, D. (2023). Estimating risk of antidepressant withdrawal from a review of published data. CNS Drugs, 37(2), 143-157.
Jones, B. D., & Husain, M. I. (2021). Tranquilizer/Anxiolytics: Benzodiazepines (intermediate-acting)âAlprazolam, Bromazepam, Clonazepam, Lorazepam. In P. Riederer, G. Laux, T. Nagatsu, W. Le, & C. Riederer (Eds.), NeuroPsychopharmacotherapy (pp. 1-12). Springer Cham.
Jufer-Phipps, R. A., & Levine, B. S. (2020). Benzodiazepines. In B. S. Levine & S. Kerrigan (Eds.), Principles of forensic toxicology (pp. 317-331). Springer Cham.
Meng, L. C., Lin, C. W., Chuang, H. M., Chen, L. K., & Hsiao, F. Y. (2023). Benzodiazepine use during pregnancy and risk of miscarriage. JAMA Psychiatry, 1-17.
NHS. (2023). Pregnancy, breastfeeding and fertility while taking lorazepam. National Health Services.
NIH. (2022). Benzodiazepines and opioids. National Institute of Drug Abuse.
OHA. (2021). How to approach a benzodiazepine taper.
OTIS. (2021). Sertraline (ZoloftÂŽ). National Library of Medicine.
Perananthan, V., & Buckley, N. A. (2021). Opioids and antidepressants: Which combinations to avoid. Australian Prescriber, 44(2), 41-44.
Scognamiglio, P., Iniziato, V., La Pia, S., & Martiadis, V. (2023). A no-win situation: Psychiatrists navigating competing obligations between free will, paternalism, duty of care, and position of guarantee. Mental Wellness, 1(1), 1-4.
Shariatpanahi, M., Faramarzi, M., Barat, S., Farghadani, A., & Shirafkan, H. (2023). Prevalence and risk factors of prenatal anxiety disorders: A cross-sectional study. Health Science Reports, 6(8), 1-9.
